BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18536523)

  • 1. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted trials in ovarian cancer.
    Ledermann JA; Raja FA
    Gynecol Oncol; 2010 Oct; 119(1):151-6. PubMed ID: 20591473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
    Morin MJ
    Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New drugs and targeted therapeutic agents in ovarian cancer].
    de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
    Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody therapy of ovarian cancer.
    Nicodemus CF; Berek JS
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of anti-angiogenic therapy in ovarian cancer (review).
    Conteduca V; Kopf B; Burgio SL; Bianchi E; Amadori D; De Giorgi U
    Int J Oncol; 2014 May; 44(5):1417-24. PubMed ID: 24626312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    Wanebo HJ; Argiris A; Bergsland E; Agarwala S; Rugo H
    Cancer Metastasis Rev; 2006 Jun; 25(2):279-92. PubMed ID: 16770540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies: a nursing perspective.
    Kay P
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):1-4. PubMed ID: 16616280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
    Dinh P; Harnett P; Piccart-Gebhart MJ; Awada A
    Crit Rev Oncol Hematol; 2008 Aug; 67(2):103-12. PubMed ID: 18342536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising molecular targets in ovarian cancer.
    Blagden S; Gabra H
    Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD; Moehler M
    Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid cancer molecular signaling pathways and use of targeted therapy.
    Kundra P; Burman KD
    Endocrinol Metab Clin North Am; 2007 Sep; 36(3):839-53, viii. PubMed ID: 17673131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
    Markman M
    Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining molecular therapeutics with radiotherapy for head and neck cancer.
    Riesterer O; Milas L; Ang KK
    J Surg Oncol; 2008 Jun; 97(8):708-11. PubMed ID: 18493923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of targeted therapy in ovarian cancer.
    Banerjee S; Kaye S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective.
    Awada A; Mano M; Hendlisz A; Piccart M
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):53-60. PubMed ID: 14748657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.